Top Page
PainChek Ltd
(Sydney:PCK)
PainChek Ltd (PCK) vs. iShares MSCI Australia ETF (EWA)
PainChek Ltd Business Overview & Revenue Model
PainChek Ltd Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.03M | 2.67M | 1.95M | 978.57K | 214.80K | 248.19K |
| Gross Profit | 856.59K | 726.66K | 712.51K | -258.82K | -424.21K | -16.98K |
| EBITDA | -8.14M | -9.49M | -8.61M | -6.80M | -8.91M | -13.15M |
| Net Income | -8.17M | -8.31M | -7.57M | -5.72M | -6.06M | -12.39M |
Balance Sheet | ||||||
| Total Assets | 3.72M | 4.18M | 2.80M | 6.65M | 11.81M | 6.22M |
| Cash, Cash Equivalents and Short-Term Investments | 2.00M | 3.56M | 2.51M | 6.14M | 11.42M | 6.12M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.47M | 2.89M | 2.13M | 1.83M | 3.57M | 2.09M |
| Stockholders Equity | 1.25M | 1.29M | 668.13K | 4.82M | 8.24M | 4.13M |
Cash Flow | ||||||
| Free Cash Flow | -7.82M | -7.16M | -6.34M | -7.02M | -4.18M | -1.93M |
| Operating Cash Flow | -7.79M | -7.13M | -6.32M | -7.00M | -4.12M | -1.89M |
| Investing Cash Flow | -29.68K | -34.25K | -12.44K | -21.96K | -60.03K | -45.56K |
| Financing Cash Flow | 8.67M | 8.21M | 2.70M | 1.75M | 9.48M | 3.51M |
PainChek Ltd Technical Analysis
PainChek Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | AU$17.93M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
55 Neutral | AU$62.63M | ― | -457.46% | ― | 21.93% | 10.34% | |
48 Neutral | AU$2.43B | 4.28 | -64.25% | 2.90% | 35.15% | 13.63% | |
40 Neutral | AU$23.79M | ― | -104.23% | ― | ― | -17.26% | |
40 Underperform | $97.07M | ― | -99.05% | ― | ― | -34.09% | |
40 Underperform | AU$124.62M | ― | -46.65% | ― | 96.20% | 80.90% | |
36 Underperform | $21.48M | ― | -467.81% | ― | -75.71% | -8.26% |
PainChek Ltd Corporate Events
PainChek Ltd reports positive progress in obtaining US FDA De Novo clearance for its entry into the US market, which could position it as the only regulatory-cleared product in the US long-term care market. The company has launched its Infant App on the Apple Store in Australia and continues to expand its global presence with over 100,000 contracted licenses and a high customer retention rate, indicating strong market adoption and potential for future growth.
PainChek Ltd announced an upcoming investor webinar to discuss their quarterly update and financial performance. The company continues to expand its market presence with its innovative pain assessment technology, which has been adopted by over 1,800 aged care facilities and is being integrated into home care services. This expansion highlights PainChek’s commitment to enhancing pain management practices globally and its potential impact on healthcare providers and patients.
PainChek Ltd has received a $1.41 million R&D tax refund for FY24, which, along with recent capital raising, will support the completion of key milestones. The company is advancing its US FDA review for the PainChek Adult App, with regulatory clearance anticipated in the first half of 2025, potentially opening a $100 million per annum market in US aged care. Additionally, PainChek has launched its Infant App on the Apple App Store in Australia, receiving positive feedback from parents for its ease of use and effectiveness. The company plans a broader marketing rollout in Q2 2025, supported by strategic partnerships and user insights.
PainChek Ltd has announced the issuance of 36 million unquoted equity securities, specifically UW Options expiring on March 24, 2026, with an exercise price of $0.05. This move is part of previously announced transactions and is not intended for quotation on the ASX, potentially impacting the company’s financial strategy and stakeholder interests.
PainChek Ltd has announced the issuance of 27,549,501 new unquoted options, set to expire on March 24, 2026, with an exercise price of $0.05. This move is part of the company’s strategic financial operations, potentially impacting its market position and offering stakeholders an opportunity for future investment returns.
PainChek Ltd has announced the application for quotation of 27,549,501 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions and is expected to enhance the company’s capital structure, potentially impacting its market positioning and providing opportunities for stakeholders.
PainChek Ltd has updated its previous announcement to correct the number of clients and digital assessments, now reporting over 1,800 clients and 10 million assessments. This update reflects the company’s growing impact in the healthcare industry, particularly in aged care facilities, where its AI-driven pain assessment tool enhances diagnostic accuracy and streamlines care processes. The company’s expansion into home care services further strengthens its market position and offers significant benefits for stakeholders, including improved engagement with healthcare professionals and compliance support.
PainChek Ltd announced its participation in the NWR Virtual Healthcare Conference, where CEO Philip Daffas will present the company’s innovative pain assessment solutions. This participation highlights PainChek’s ongoing efforts to enhance its industry positioning and expand its market reach, particularly in home care and disability services. The company’s technology, which has been validated in clinical studies, continues to support accurate pain management for individuals with conditions affecting their ability to self-report pain, including dementia and disability.
PainChek Ltd has announced the issuance of new unquoted equity securities, specifically options expiring on March 3, 2026, with an exercise price of $0.05. This issuance involves a total of 6,606,786 securities and is part of the company’s ongoing financial strategies. The announcement signifies PainChek’s efforts to enhance its financial flexibility and potentially strengthen its market position by leveraging these securities.
PainChek Ltd has announced the application for quotation of 6,606,786 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions and is expected to enhance the company’s market presence and provide additional capital for its operations, potentially impacting its growth and stakeholder value positively.
PainChek Ltd has announced the issuance of unquoted equity securities, specifically UW Options expiring on March 3, 2026, with an exercise price of $0.05. This issuance involves a total of 168,657,644 securities and is part of a previously announced transaction, which may impact the company’s financial structure and stakeholder interests.
PainChek Ltd reported a 21% increase in total revenue and other income for the half-year ending December 31, 2024, compared to the previous year, driven by a 27% rise in revenue from continuing operations and a 14% increase in R&D grants. Despite this growth, the company recorded a net loss of $3.16 million, a slight improvement from the previous period. The financial report highlights a concern regarding the company’s going concern status, as noted by the independent auditor, which may impact its future operations and stakeholder confidence.
PainChek Ltd announced the results of its General Meeting, where a resolution was successfully passed. The company continues to enhance its industry positioning with its innovative pain assessment technology, which has been widely adopted in over 1,800 aged care facilities and is undergoing FDA review in the United States. This expansion into home care services and partnerships with disability service providers highlights its commitment to broadening its impact on pain management practices, benefiting stakeholders such as nurses, carers, and healthcare professionals.